Please Wait.....
Report
New Zealand Oral Anti-Diabetic Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029
Market Report I 2024-02-17 I 70 Pages I Mordor Intelligence
The New Zealand Oral Anti-Diabetic Drug Market size is estimated at USD 323 million in 2024, and is expected to reach USD 367.23 million by 2029, growing at a CAGR of 2.60% during the forecast period (2024-2029).
The likelihood of having type 1 diabetes increased when COVID-19 was discovered. Young pediatric patients and older adult patients with COVID-19 had the highest risk. Patients with type 1 diabetes were more likely to contract the virus and experience potentially catastrophic side effects such as diabetic ketoacidosis. Patients required access to diabetes services and get high-quality clinical care, which includes diabetes screening, education, monitoring of complications, and control. The hormone insulin encourages the liver, muscle, and fat cells to absorb glucose from the blood in order to regulate blood sugar levels. It facilitates the absorption of glucose for cellular energy utilization by cells. When the pancreas is unable to create enough insulin, type 1 diabetes develops. Diabetes is frequently thought of as a condition linked to lifestyle. Because of the growing world population, the disease's prevalence has substantially increased over time. Insulin is necessary for everyone with Type 1 diabetes and 10% to 25% of people with Type 2 diabetes or over 100 million people globally. Despite the fact that insulin has been used to treat diabetes for more than 90 years, more than half of the individuals in New Zealand who require it still do not have access to it or can afford it. Insulin As people with type-1 diabetes cannot produce insulin on their own. They require medications and delivery methods. Those with type-2 diabetes also require insulin, especially if they are having problems managing their condition.
New Zealand Oral Anti-Diabetic Drug Market Trends
Sodium-glucose Cotransport-2 (SGLT-2) inhibitor Segment Occupied the Highest Market Share in New Zealand Oral Anti-Diabetic Drugs Market in 2022
In terms of revenue, the Sodium-glucose Cotransport-2 (SGLT-2) inhibitor segment is anticipated to lead the India Oral Anti-Diabetic Drugs Market and post a CAGR of over 2.8% during the course of the forecast year.
A hormone produced in the gut called Sodium-glucose Cotransport-2 (SGLT-2) inhibitor promotes the release of insulin, decreases the secretion of glucagon, prevents gastric emptying, and reduces appetite. SGLT2 plasma levels are low during a fast and quickly rise following a meal. By enzymatic breakdown by dipeptidyl peptidase-4 (DPP-4) and renal clearance, circulating levels of intact SGLT2 rapidly drop. SGLT2 operates on GLP-1 receptors found in peripheral tissue, pancreatic islet cells, and other organs and plays a critical role in glucose regulation. By a number of mechanisms, including increased glucose-dependent insulin secretion, delayed stomach emptying, and decreased postprandial glucagon and food intake, GLP-1-based medicines (GLP1-RA and DPP-4 inhibitors) impact glucose control. Obesity, physical inactivity, hypertension, and hyperlipidemia are all frequently linked to T2DM. Those who have their blood sugar levels improperly managed to risk developing long-term microvascular and macrovascular problems. The quality of life and life expectancy is greatly decreased by these problems. T2DM is a complex disorder that places a heavy strain on the patient, their extended family, and the healthcare system. T2DM is thought to affect 5% of New Zealanders, and by 2040, that number is expected to rise to 7% of the population. Compared to other ethnic groups in New Zealand, Pacific, Mori, and South Asian communities are more likely to have T2DM and experience difficulties from the condition.
Increasing Diabetes Population in New Zealand is driving the market.
In New Zealand, "primary care" and "secondary care" are widely used to denote different types of medical treatment. The majority of people frequently seek out primary care as their initial form of treatment. This is typically your family physician or general practitioner. Despite the fact that patients must pay for this treatment, those with modest incomes typically qualify for a reduced price. All children under the age of six are eligible to get free doctor visits in New Zealand. Depending on the doctor, GP visits normally cost between NZ 45 and NZ 55. There is no additional cost for a GP visit for foreign travelers. Patients may be directed to secondary care, which is often thought of as specialized treatment, after seeing their physician. Patients may be directed to secondary care, which is often thought of as specialized treatment, after seeing their physician. A few examples of the services that are often managed outside of the major hospitals are hospital services, specialty diabetic services, specialist eye services, specialist renal services, and specialist diabetic services. If a patient is having problems with their diabetes or, in some situations, if they require insulin to treat their diabetes, they can ask to be referred to specialized diabetic services. Some diabetes doctors also run private practices, even though the professional services are free. While the precise cause of type-2 diabetes is unknown, type-1 diabetes is thought to have an unknown origin. The prevalent rate of type-2 diabetes doubled in the last ten years ago. Type 1 diabetes mellitus (T1DM) has increased significantly during the past 20 years. The biggest risk factor for T1DM and the cause of this increase in frequency is the growth in obesity. One of the chronic conditions with the quickest rate of rise in New Zealand is diabetes. Many investigations and surveys have revealed a substantial increase in the population of diabetes, which can be attributed to lifestyle choices.
New Zealand Oral Anti-Diabetic Drug Industry Overview
New Zealand's oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence. While the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Oral Anti-diabetic drugs (Value and Volume, 2017 - 2028)
5.1.1 Biguanides
5.1.1.1 Metformin
5.1.2 Alpha-Glucosidase Inhibitors
5.1.2.1 Alpha-Glucosidase Inhibitors
5.1.3 Dopamine D2 receptor agonist
5.1.3.1 Bromocriptin
5.1.4 SGLT-2 inhibitors
5.1.4.1 Invokana (Canagliflozin)
5.1.4.2 Jardiance (Empagliflozin)
5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
5.1.4.4 Suglat (Ipragliflozin)
5.1.5 DPP-4 inhibitors
5.1.5.1 Onglyza (Saxagliptin)
5.1.5.2 Tradjenta (Linagliptin)
5.1.5.3 Vipidia/Nesina(Alogliptin)
5.1.5.4 Galvus (Vildagliptin)
5.1.6 Sulfonylureas
5.1.6.1 Sulfonylureas
5.1.7 Meglitinides
5.1.7.1 Meglitinides
6 MARKET INDICATORS
6.1 Type-1 Diabetic Population (2017 - 2028)
6.2 Type-2 Diabetic Population (2017 - 2028)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Takeda
7.1.2 Novo Nordisk
7.1.3 Pfizer
7.1.4 Eli Lilly
7.1.5 Janssen Pharmaceuticals
7.1.6 Astellas
7.1.7 Boehringer Ingelheim
7.1.8 Merck And Co.
7.1.9 AstraZeneca
7.1.10 Bristol Myers Squibb
7.1.11 Novartis
7.1.12 Sanofi
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security